Roliten - Instructions For The Use Of Tablets, Price, Reviews, Analogues

Table of contents:

Roliten - Instructions For The Use Of Tablets, Price, Reviews, Analogues
Roliten - Instructions For The Use Of Tablets, Price, Reviews, Analogues

Video: Roliten - Instructions For The Use Of Tablets, Price, Reviews, Analogues

Video: Roliten - Instructions For The Use Of Tablets, Price, Reviews, Analogues


Roliten: instructions for use and reviews

  1. 1. Release form and composition
  2. 2. Pharmacological properties
  3. 3. Indications for use
  4. 4. Contraindications
  5. 5. Method of application and dosage
  6. 6. Side effects
  7. 7. Overdose
  8. 8. Special instructions
  1. 9. Application during pregnancy and lactation
  2. 10. Use in childhood
  3. 11. Drug interactions
  4. 12. Analogs
  5. 13. Terms and conditions of storage
  6. 14. Terms of dispensing from pharmacies
  7. 15. Reviews
  8. 16. Price in pharmacies

Latin name: Roliten

ATX code: G04BD07

Active ingredient: tolterodine (tolterodine)

Manufacturer: Ranbaxy Laboratories Ltd. (India)

Description and photo update: 2018-26-10

Prices in pharmacies: from 459 rubles.


Film-coated tablets, Roliten
Film-coated tablets, Roliten

Roliten is an m-anticholinergic blocker that has antispasmodic and anticholinergic effects.

Release form and composition

Dosage form of the drug Roliten - film-coated tablets: biconvex, round, color from almost white to white (10 pcs. In blisters, in a carton of 3 or 6 blisters).

Composition for 1 tablet:

  • active substance: tolterodine tartrate - 2 mg;
  • auxiliary components: microcrystalline cellulose, colloidal silicon dioxide, calcium hydrogen phosphate, sodium carboxymethyl starch, magnesium stearate;
  • film casing: white opadry dye OY-S-58910 (titanium dioxide, hypromellose, talc, macrogol 400), purified water (evaporates during the production process).

Pharmacological properties


The active component of Roliten, tolterodine, is an antagonist of m-cholinergic receptors, concentrated in the salivary glands and bladder. It reduces the contractile activity of the bladder and reduces salivation. Rolliten allows partial emptying of the bladder, increasing the amount of residual urine and decreasing the pressure of the muscular membrane of the bladder (detrusor). A stable therapeutic effect of the drug is achieved 4 weeks after the start of treatment. Tolterodine, as well as 5-hydroxymethyl, its active metabolite, exhibit high specificity for muscarinic receptors and are selective for bladder receptors (in comparison with salivary gland receptors).


The main pharmacokinetic characteristics of tolterodine:

  • absorption: after oral administration, tolterodine is rapidly absorbed from the gastrointestinal tract (gastrointestinal tract), reaching C max (maximum serum concentration) after 1–3 hours after administration. C max increases in proportion to the dose in the range of 1–4 mg. The indicator of absolute bioavailability is up to 65% with reduced metabolism (in persons deprived of CYP2D6) and up to 17% with increased metabolism, which is typical for most patients. Food intake does not affect the exposure of unbound tolterodine and its active metabolite in patients with increased metabolism, however, when tolterodine is taken with food, its level increases;
  • distribution: it takes up to 2 days to reach an equilibrium concentration of a substance; V d (volume of distribution) - 113 liters;
  • metabolism: metabolic processes occur mainly in the liver with the participation of the polymorphic enzyme CYP2D6, resulting in the formation of a pharmacologically active 5-hydroxymethyl metabolite. With further metabolism, 5-carboxylic acid and its N-dealkylated metabolites are formed. In patients with reduced metabolism due to deficiency of the CYP2D6 enzyme, tolterodine undergoes dealkylation by CYP2D6 isoenzymes with the formation of pharmacologically inactive N-dealkylated tolterodine. Tolterodine and its active metabolite bind mainly with alpha-1-acid glycoprotein (orosomucoid), unbound fractions are 3.7% and 36%, respectively;
  • excretion: with increased metabolism, the systemic clearance rate reaches 30 liters per hour, T 1/2 (half-life) is 2-3 hours. For the 5-hydroxymethyl metabolite, T 1/2 increases to 3-4 hours. Elimination of a radioactive label after taking 14 C-tolterodine: with urine ~ 77%, with feces ~ 17%, including unchanged <1%, in the form of an active metabolite ~ 4%. Of the total amount of tolterodine excreted in the urine, the carboxylated metabolite is 51%, the corresponding dealkylated metabolite is ~ 29%.

With a reduced metabolism, a decrease in the clearance of tolterodine and an increase in its T 1/2 to 10 hours leads to an approximately 7-fold increase in its concentration level against the background of undetectable 5-hydroxymethyl metabolite concentrations. As a result, with the same dosage regimen, the AUC value (area under the concentration-time curve) of tolterodine in patients with reduced metabolism is close to the sum of the AUC of tolterodine and its active 5-hydroxymethyl metabolite in individuals with increased metabolism. Thus, Roliten's safety, tolerability and clinical efficacy are the same for different phenotypes.

In patients with liver cirrhosis, the AUC of tolterodine and its active 5-hydroxymethyl metabolite is approximately doubled.

Indications for use

According to the instructions, Roliten is recommended to be used for the treatment of hyperreflexia (hyperactivity, instability) of the bladder, manifested by urinary incontinence and / or frequent urge to urinate.



  • delay in urination;
  • angle-closure glaucoma, not amenable to drug therapy;
  • myasthenia gravis (myasthenia gravis);
  • ulcerative colitis, including with toxic enlargement of the large intestine (megacolon);
  • the period of pregnancy and breastfeeding;
  • childhood;
  • individual hypersensitivity to the components of the drug.

Relative contraindications for which Roliten should be used with caution: obstructive gastrointestinal lesions, obstruction of the urinary tract, irreducible hernia, neuropathy.

Instructions for use of Roliten: method and dosage

Roliten tablets are taken orally.

The recommended dosing regimen for adult patients: 2 mg (1 tablet) 2 times a day.

Patients with hepatic / renal failure, as well as the development of side effects should be reduced to a dose of 1 mg (1 / 2 tablets) 2 times per day.

After six months, the effectiveness of treatment should be assessed and the need to continue it should be decided.

Side effects

During therapy with Roliten, the following side effects are possible (gradation: often - more than 10%; infrequently - from 1 to 10%; rarely - less than 1%):

  • reactions to the anticholinergic effect of the drug: often - dry mouth; infrequently - xerophthalmia (decreased lacrimation), accommodation disturbances, dry skin; rarely - urinary retention;
  • digestive system: infrequently - abdominal pain, dyspepsia, constipation, flatulence, vomiting; rarely - gastroesophageal reflux;
  • central and peripheral nervous system: infrequently - dizziness, headache, drowsiness, paresthesia, nervousness; rarely - impaired consciousness;
  • other reactions: infrequently - fatigue, weakness, weight gain; rarely - allergic reactions, chest pains, flushing of the face.


The maximum single dose of tolterodine tartrate received by the volunteers was 12.8 mg. In this case, the following side reactions were observed: the most important - painful urge to urinate and accommodation disturbances; possible - hallucinations, hyperexcitation, tachycardia, respiratory failure, convulsions, urinary retention, dilated pupils.

The first stage of treatment is the maximum possible removal of Rolten from the gastrointestinal tract: gastric lavage, intake of activated carbon.

Further, symptomatic therapy is carried out according to the indications:

  • pronounced central anticholinergic effects (including hallucinations) - physostigmine;
  • convulsions or severe agitation - benzodiazepines;
  • tachycardia - beta-blockers;
  • respiratory failure - artificial respiration;
  • urinary retention - catheterization;
  • dilated pupils - pilocarpine in the form of eye drops and / or moving the patient into a room without lighting.

special instructions

Before starting therapy, it is necessary to exclude the organic causes of frequent / urgent urge to urinate.

Influence on the ability to drive vehicles and complex mechanisms

Accommodation disorders and a decrease in the speed of psychomotor reactions caused by the use of Roliten can affect the ability to perform potentially dangerous activities. In each case, this possibility should be considered separately, after assessing the patient's response to the drug.

Application during pregnancy and lactation

Roliten is contraindicated for use during pregnancy and lactation. Women of reproductive age need to use reliable methods of preventing pregnancy while undergoing tolterodine therapy.

Pediatric use

Roliten is not used in pediatrics, since the safety and effectiveness of its use in children have not been studied.

Drug interactions

  • other anticholinergic substances / drugs: it is possible to increase the therapeutic effect of Roliten and increase the undesirable effects;
  • m-cholinomimetics: the therapeutic effect of tolterodine may decrease;
  • metoclopramide and cisapride: possible weakening of their effectiveness;
  • other drugs metabolized by isoenzymes of the cytochrome P 450 system CYP2D6 or CYP3A4, or which are inhibitors or inducers of these isoenzymes: their pharmacokinetic interaction with tolterodine is likely;
  • fluoxetine (a strong inhibitor of CYP2D6, metabolized to norfluoxetine, a CYP3A4 inhibitor): slightly increases the total AUC of tolterodine and its active 5-hydroxymethyl metabolite, without causing clinically significant interactions;
  • strong inhibitors of CYP3A4 [macrolide antibiotics (erythromycin and clarithromycin) or antifungal agents (ketoconazole, itraconazole and miconazole)]: their simultaneous use with Roliten should be avoided;
  • warfarin, combined oral contraceptives containing ethinylestradiol / levonorgestrel: according to clinical trials, they did not interact with Rolten;
  • cytochrome P 450 isoenzymes (CYP2D6, CYP2C19, CYP3A4 or CYP1A2): Clinical studies using metabolic probes have not provided any indication that tolterodine is capable of inhibiting their activity.


Roliten's analogues are Urotol, Uroflex, Detrusitol, etc.

Terms and conditions of storage

Store at a temperature of 25 ° C out of the reach of moisture. Keep out of the reach of children.

Shelf life is 4 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Roliten

According to reviews, Roliten is a fairly effective drug for problems with uncontrolled urination. Patients note that the therapeutic effect of the tablets diminishes over time, presumably due to addiction.

Many people think that this drug is optimal in terms of efficiency / cost ratio, but because of this it is inaccessible and incredibly difficult to find in pharmacies.

Price for Roliten in pharmacies

Approximate price for Roliten (30 pcs per pack) - 455-507 rubles.

Roliten: prices in online pharmacies

Drug name



Roliten 2 mg film-coated tablets 30 pcs.

459 r


Anna Kozlova
Anna Kozlova

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Popular by topic